Blood products giant CSL will continue to manufacture 50 million doses of the AstraZeneca COVID-19 vaccine, despite it now only being recommended for Australians who are over 50, creating a surplus.

Given the median age of the population is 37, according to the Australian Bureau of Statistics, the change in guidance from the government will result in there being more AstraZeneca vaccines than are needed.